- Evatanepag
-
- $64.00
-
2026-04-21
- CAS:223488-57-1
- Purity: 99.68%
- Supply Ability: 10g
|
| | 2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid Basic information |
| Product Name: | 2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid | | Synonyms: | EVATANEPAG;CP-533536;CP 533536;CP-533536;CP 533536;CP533536;(3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)-phenoxy)-acetic acid;Evatanepag (CP-533536);CS-2325;2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid;CP-533536 free acid;Acetic acid, 2-[3-[[[[4-(1,1-dimethylethyl)phenyl]methyl](3-pyridinylsulfonyl)amino]methyl]phenoxy]- | | CAS: | 223488-57-1 | | MF: | C25H28N2O5S | | MW: | 468.57 | | EINECS: | | | Product Categories: | | | Mol File: | 223488-57-1.mol | ![2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid Structure](CAS2/GIF/223488-57-1.gif) |
| | 2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid Chemical Properties |
| storage temp. | Sealed in dry,Store in freezer, under -20°C | | solubility | DMSO:32.0(Max Conc. mg/mL);68.29(Max Conc. mM) | | form | Solid | | color | White to off-white |
| | 2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid Usage And Synthesis |
| Uses | Evatanepag is an EP2 receptor selective prostaglandin E2 agonist that helps induce bone growth. | | Definition | ChEBI: Evatanepag is a monocarboxylic acid. | | in vivo | Evatanepag (0.3-3.0 mg/kg, directly injected into the marrow cavity of the tibia) promotes bone formation in rats[1].
Evatanepag (0.3, 3.0 mg/kg, intranasal administration, from day1 to day4) reduces HDM aeroallergen-induced increased RL response to methacholine in mice[2].
Evatanepag (1 mg/kg, intravenous injection) demonstrates high i.v. clearance (Cl: 56 mL/min/kg) and a short half-life (t1/2: 0.33 h)[1].
| Animal Model: | Rats[1] | | Dosage: | 0.3, 1.0, 3.0 mg/kg | | Administration: | Directly injected into the marrow cavity of the tibia
| | Result: | Dose-dependently increased in bone area, bone mineral content, bone mineral density. |
| Animal Model: | HDM (house dust mite)-sensitized BALB/c mice[2] | | Dosage: | 0.3 mg/kg, 3 mg/kg | | Administration: | Intranasal administration, from day1 to day4
| | Result: | Prevented aeroallergen-driven increased RL (lung resistance) at 0.3 mg/kg.
Prevented the enhanced MC activity by approximately 48% at 3 mg/kg.
|
| | IC 50 | EP2 |
| | 2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid Preparation Products And Raw materials |
|